<DOC>
	<DOC>NCT01093326</DOC>
	<brief_summary>This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.</brief_summary>
	<brief_title>Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>1. Patients who completed study treatment at their regular Week 24 (End of treatment) visit within the core study AC058B201. 2. Signed informed consent for participating in the extension study. 1. Any clinically relevant medical or surgical condition, which, in the opinion of the investigator, would put the patient at risk by participating in the extension study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>